title: Excessive long-term platelet inhibition with prasugrel or ticagrelor and risk of infection: another hidden danger?
authors: 1HeartDrug Research Laboratories, Johns Hopkins University, Osler Medical Building, 7600 Osler Drive, Suite 307, Towson, Maryland, 21204; 2Wegmans Pharmacy, Ithaca, NY; 3Silesian Center for Heart Diseases, Szpitalna 2, 41-800 Zabrze, Poland.
authors: Nodar
authors: N
authors: Kipshidze
authors: Elizabeth
authors: E
authors: Platonova
authors: James J
authors: JJ
authors: DiNicolantonio
authors: Wiktor
authors: W
authors: Kuliczkowski
authors: Victor L
authors: VL
authors: Serebruany
mesh_terms: D000241:Adenosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000818:Animals; D006801:Humans; D007239:Infections / Q000139:chemically induced* / Q000453:epidemiology; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D000068799:Prasugrel Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects*; D000077486:Ticagrelor; D013997:Time Factors
chemical_list: D010975:Platelet Aggregation Inhibitors; D000068799:Prasugrel Hydrochloride; D000077486:Ticagrelor; D000241:Adenosine